WCN25-661 Switching Strategies: Evaluating the Safety and Efficacy of Non-Steroidal Mineralocorticoid Antagonists (ns MRA) in Spironolactone- non tolerant Post-Transplant Recipients

WCN25-661 Switching Strategies: Evaluating the Safety and Efficacy of Non-Steroidal Mineralocorticoid Antagonists (ns MRA) in Spironolactone- non tolerant Post-Transplant Recipients

Saved in:

Bibliographic Details
Main Authors:	Chakradhar Arepalli, Dharanidhar Reddy, Sai Sindhu Singh
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924028845
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Current Application of Mineralocorticoid Antagonist (MRA) in Heart Failure and CKD: Does Non-Steroidal Drug Add Novel Insights
by: Irene Carlino, et al.
Published: (2025-07-01)

Non-Steroidal Mineralocorticoid Receptor Antagonists: A Paradigm Shift in the Management of Diabetic Nephropathy
by: Justine Huart, et al.
Published: (2025-01-01)

Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628.
by: Frank Y Ma, et al.
Published: (2015-01-01)

Observation of the therapeutic effect of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, in patients with non-diabetic CKD
by: Fang Li, et al.
Published: (2025-12-01)

Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists
by: Biykem Bozkurt, et al.
Published: (2025-07-01)

Mineralocorticoid receptor antagonists reduce inflammatory signaling independent of myofiber mineralocorticoid receptor
by: Jeovanna Lowe, et al.
Published: (2025-12-01)

Focus on Finerenone, a Non-Steroidal MRA in Diabetic Kidney Disease. What Physicians Should Know?
by: Dwaipayan Sarathi CHAKRABORTY, et al.
Published: (2022-03-01)

The use of mineralocorticoid antagonists in chronic heart failure
by: Andrea Szegedi, et al.
Published: (2025-07-01)

ALDOSTERONE ANTAGONISTS. MODERN VIEWS ON THE MECHANISM OF ACTION AND EFFECTS OF SPIRONOLACTONE
by: V. I. Podzolkov, et al.
Published: (2017-05-01)

Non-steroidal mineralocorticoid receptor antagonist finerenone inhibits peritoneal fibrosis induced by high-glucose dialysate via regulating enhancer of zeste homolog 2 (EZH2) expression
by: Dandan Chen, et al.
Published: (2025-12-01)

THE USE OF MINERALOCORTICOID RECEPTOR ANTAGONISTS IN THE PRE VENTION OF ATRIAL FIBRILLATION
by: N. T. Vatutin, et al.
Published: (2019-07-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023-10-01)

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
by: B. B. Gegenava, et al.
Published: (2015-09-01)

Treatment Patterns, Adverse Events, and Clinical Outcomes with Steroidal Mineralocorticoid Receptor Antagonists: A Retrospective Analysis of Administrative Claims Data (RELICS)
by: Richard EL, et al.
Published: (2025-02-01)

Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases
by: Jiao Wang, et al.
Published: (2025-08-01)

Spironolactone is an antagonist of NRG1‐ERBB4 signaling and schizophrenia‐relevant endophenotypes in mice
by: Michael C Wehr, et al.
Published: (2017-07-01)

Adrenal venous sampling outcomes with and without mineralocorticoid receptor antagonists in primary aldosteronism
by: Sittikul Thipbumrung, et al.
Published: (2025-07-01)

Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice
by: Maria Alfarano, MD, PhD, et al.
Published: (2025-06-01)

WCN25-2677 INCLISIRAN (SYNTHETIC si RNA) : A PROMISING TREATMENT FOR DYSLIPEDEMIA IN RENAL DISEASE PATIENTS
by: Chakradhar Arepalli, et al.
Published: (2025-02-01)

Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials
by: Paula Dibo, et al.
Published: (2025-08-01)

Evidence for the use of a nonsteroidal mineralocorticoid receptor antagonist for the treatment of chronic kidney disease
by: Mariana Morais David Pliças, et al.
Published: (2025-03-01)

WCN25-4241 CENTRAL VEIN STENOSIS -CLINICAL PRESENTATION ,INTERVENTION AND OUTCOME AT OUR CENTRE
by: Chakradhar Arepalli, et al.
Published: (2025-02-01)

Mineralocorticoid Receptor Antagonist Use Among Patients With Chronic Kidney Disease Who Transitioned to Dialysis
by: Eric M. Tong, MD, et al.
Published: (2025-04-01)

Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease
by: Akshyaya Pradhan, et al.
Published: (2024-12-01)

Non-invasive arterial input function estimation using an MRA atlas and machine learning
by: Rajat Vashistha, et al.
Published: (2025-05-01)

WCN25-3673 CHRONIC HEMODIALYSIS: A UNIQUE CHALLENGE TO WOMEN’S BONE HEALTH, MENSTRUAL DISTURBANCES AND ITS ASSOCIATION WITH HYPERPROLACTINEMIA, NUTRITIONAL AND MENTAL STATUS, AND THEIR IMPACT ON QUALITY OF LIFE - A PROSPECTIVE OBSERVATIONAL STUDY
by: Elayaperumal Indhumathi, et al.
Published: (2025-02-01)

Recent Advances and Perspectives on the Use of Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and Chronic Kidney Disease: A Review
by: Kisho Miyasako, et al.
Published: (2024-12-01)

Association Between Mineralocorticoid Receptor Antagonist Use With Worsening Renal Function and Prognosis in Patients With Acute Heart Failure
by: Yudai Fujimoto, et al.
Published: (2025-07-01)

WCN24-2699 ANTIPROTEINURIC EFFECT OF SPIRONOLACTONE IN KIDNEY TRANSPLANT RECIPIENTS DURING A 5-YEAR FOLLOW-UP
by: João Antônio Pessoa de Freitas, et al.
Published: (2024-04-01)

The role of free radical oxidation in the kidneys in the nephroprotective action of eplerenone, a mineralocorticoid receptor antagonist, in experimental diabetes mellitus
by: A. Yu. Zharikov, et al.
Published: (2021-07-01)

Evaluation of HOP-MRA for post-coil embolization assessment of cerebral aneurysms: a comparative study with 3D-TOF MRA
by: Kouichi Asahi
Published: (2025-05-01)

Spironolactone and metformin combination therapy as a potential non-hormonal treatment for management of hyperandrogenic symptoms of polycystic ovarian syndrome
by: Irene Karderinis, et al.
Published: (2025-07-01)

Mineralocorticoid Receptor Blocker Prevents Mineralocorticoid Receptor–Mediated Inflammation by Modulating Transcriptional Activity of Mineralocorticoid Receptor–p65–Signal Transducer and Activator of Transcription 3 Complex
by: Naoto Kuyama, et al.
Published: (2024-09-01)

Protective Effects of Selective Mineralocorticoid Receptor Antagonist in Alport Syndrome on Top of Renin-Angiotensin-System/ Sodium-Glucose Transporter 2 Blockade
by: Zhuo-ran Song, et al.
Published: (2024-03-01)

FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes
by: M. S. Shamkhalova, et al.
Published: (2023-12-01)

Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis
by: Chien‐Wei Huang, et al.
Published: (2025-02-01)

CTA and MRA findings of a persistent hypoglossal artery
by: Rebeca de J. Ramos-Sanchez, et al.
Published: (2025-04-01)

Model-Informed Dose Optimization of Spironolactone in Neonates and Infants
by: Amira Soliman, et al.
Published: (2025-03-01)

Comparison between non-contrast-enhanced MRA and contrast-enhanced CTA in the assessment of hepatic arterial vasculature of donors before liver transplantation
by: Dalia Ibrahim Aggour, et al.
Published: (2024-12-01)

Role of Magnetic Resonance Arthrography (MRA) in the Diagnosis of Shoulder Injuries
by: Prateek Awasthi, et al.
Published: (2025-06-01)